Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer

British Journal of Cancer

Volumn 79, Issue 9-10, 1999, Pages 1500-1507

  Hohaus, S ^a   Funk, L ^a   Martin, S ^a   Schlenk, R F ^a   Abdallah, A ^a   Hahn, U ^a   Egerer, G ^a   Goldschmidt, H ^a   Schneeweiss A ^a   Fersis, N ^a   Kaul, S ^a   Wallwiener, D ^a   Bastert, G ^a   Haas, R ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Breast cancer; High dose chemotherapy; Peripheral blood stem cell transplantation; Prognostic indicators; Tumour cells

Indexed keywords

ADJUVANT; CARBOPLATIN; CD34 ANTIGEN; EPIRUBICIN; ESTROGEN RECEPTOR; GOSERELIN; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; AUTOGRAFT; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033020372     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690239     Document Type: Article

References (25)

1. Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy Jr PL, Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO and Horowitz MM (1997) High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15: 1870-1879
2. Ayash LJ, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, Tepler I, Warren D, Lynch C, Gonin R, Schnipper L, Frei E and Amman K (1994) Double dose-intensive chemotherapy with autologous marrow and peripheral blood progenitor cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 12: 37-44
3. Bitran JD. Samuels B, Klein L, Hanauer S, Johnson L, Martinec J, Harris E, Kempler J and White W (1996) Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yield prolonged survival in stage IV breast cancer. Bone Marrow Transplant 17: 157-162
4. Broun ER, Sridhara R, Sledge GW, Loesch D, Kneebone PH, Hanna M, Hromas R, Cornetta K and Einhorn LH (1995) Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 13: 2050-2055
5. Cox DR (1972) Regression models and life tables. J R Stat Soc (B) 34: 187-220
6. Dunphy FR, Spitzer G, Buzdar AU, Hortobagyi GN, Horwitz LJ, Yau JC, Spinolo JA, Jagannath S, Holmes F, Wallerstein RO, Bohannan PA and Dicke KA (1990) Treatment of estrogen receptor negative or hormonally refractory breast cancer with double high-dose chemotherapy for intensification and bone marrow support. J Clin Oncol 8: 1207-1216
7. Fisher E, Sass R and Fisher B (1984) Pathologic findings from the national surgical adjuvant project for breast cancers (protocol no. 4). Cancer. 53: 712-723
8. Gianni AM, Siena S, Bregni SM, Di Nicola M, Orefice S, Cusumano F, Salvadori B, Luini A, Greco M, Zucali R, Rilke F, Zambetti M, Valagussa P and Bunadonna G (1997) Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes; five-year results. J Clin Oncol 15: 2312-2321
9. Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, Barber M, Saporito L, Woo SD, Coral F, Speclor N, Rabinowe SN, Grossbard ML, Ritz J and Nadler LM (1993) Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81: 3449-3457
10. Haas R, Möhle R, Frühauf S, Goldschmidt H, Wilt B, Flentje M, Wannenmacher M and Hunstein W (1994) Patient characteristics associated with successful mobilizing and autografting or peripheral blood progenitor cells in malignant lymphoma. Blood 83: 3787-3794
11. Haas R, Schmid H, Hahn U, Hohaus S, Goldschmidt H, Murea S, Kaufmann M, Wannenmacher M, Wallwiener D, Bastert G and Hunstein W (1997) Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer. Eur J Cancer 33: 372-378
12. Hahn U, Goldschmidt H, Salwender H, Haas R and Hunstein W (1995) Large-bore central venous catheters for the collection of peripheral blood stem cells. J Clin Apheresis 10: 12-16
13. Hohaus S, Goldschmidt H, Ehrhardt R and Haas R (1993) Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSE. Exp Hematol 21: 508-514
14. Hohaus S, Pfoersich M, Murea S, Abdallah A, Lin YS, Funk L, Voso MT, Kaul S, Schmid H, Wallwiener D and Haas R (1997) Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer. Br J Haematol 97: 881-888
15. Hohaus S, Wallwiener D, Martin S, Voso MT, Huober J, Fersis N, Bastert G and Haas R (1998) Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer. Semin Oncol 25: 7-11
16. Kaplan EL and Meier P (1958) Non-parametric estimation from incomplete observation. J Am Stat Assoc 47: 457-481
17. Lin F, van Rhee F, Goldman JM and Gross NC (1996) Kinetics of increasing BCR-ABL transcript numbers in chonic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 87: 4473-4478
18. Marks C, Halperin E, Prosnitz L, Ross M, Vredenburgh JJ, Rosner GL and Peters W (1992 Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. Int J Rad Oncol Biol Phys 23: 1021-1026
19. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC Jr, Jones R, Shpall EJ, Wu K, Rosncr G, Gilbert C, Mathias B, Consighio D, Pehosw, Henderson IC, Norotn L, Weiss R, Budman D and Huid D (1993) High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11: 1132-1143
20. Peto R and Peto J (1972) Asymptotically efficient rank invariant test procedures. J R Stat Soc (A) 135: 185 ff
21. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D, Winter C, Jansen J, Akard L, Copeland E, Kohn DJ and Werner NE. (1993) Detection and viability of tumour cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82: 1260-2610
22. Somlo G, Doroshow JH, Forman SJ, Odom-Maryon T, Lee J, Chow W, Hamasaki V, Leong L, Morgan Jr, R, Margolin K, Rasehko J, Shibata S, Teter M, Yen Y, Simpson J and Molina A (1997) High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol 15: 2882-2893
23. Yalagussa P, Bonadonna G and Veronesi U (1978) Patterns of relapse and survival following radical mastectomy: analysis of 716 consecutive patients. Cancer 41: 1170-1178
24. van der Wall E, Mooijen WJ, Baars JW, Holtkamp MJ, Schorangel JH, Richel DJ, Rutgers EJ, Slaper-Cortenbach IC, van der Schoot CE and Rodenhuis S (1995) High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br J Cancer 71: 857-862
25. van der Wall E, Schaake-Koning CC, van Zandwijk N, Baars JW, Schornagel J, Richel DJ, Rutgers EJ, Borger JH, Beijnen JH and Rodenhuis S (1996) The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis. Eur J Cancer 32A: 1490-1497